Publications by authors named "D Serafin"

Background: Ischemic heart disease is a prevalent cause of death and disability worldwide. Recent studies reported a rapid expansion of the cardiac lymphatic network upon ischemic heart injury and proposed that cardiac lymphatics may attenuate tissue edema and inflammatory mechanisms after ischemic heart injury. Nevertheless, the mechanisms through which hypoxic conditions affect cardiac lymphangiogenesis and function remain unclear.

View Article and Find Full Text PDF

Personal and structural barriers to HIV pre-exposure prophylaxis (PrEP) care result in its underutilization and premature discontinuation. A home-based PrEP program comprised of telemedicine visits and/or self-administered lab testing may address some of these barriers. Our objective was to assess the acceptability and feasibility of a home-based PrEP program among stakeholders at an urban HIV and primary care clinic.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the real-world effectiveness of the Pembrolizumab/Axitinib combination therapy for metastatic renal cell carcinoma (mRCC) in Italy, involving 170 patients treated between December 2020 and September 2023.
  • Most participants had clear-cell histology (83%), and the treatment showed a median progression-free survival (PFS) of 19.2 months, with 84.6% achieving disease control.
  • The study highlights key prognostic factors, including age and histology, that affect overall survival (OS) and establishes the combination's promise in clinical settings.
View Article and Find Full Text PDF

The adhesion receptor vascular endothelial (VE)-cadherin transduces an array of signals that modulate crucial lymphatic cell behaviors including permeability and cytoskeletal remodeling. Consequently, VE-cadherin must interact with a multitude of intracellular proteins to exert these functions. Yet, the full protein interactome of VE-cadherin in endothelial cells remains a mystery.

View Article and Find Full Text PDF

The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years. The introduction of novel combination therapies involving tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors has resulted in improved oncological outcomes compared to traditional TKI monotherapy. In this evolving paradigm, the pivotal role of the multidisciplinary tumor board is underscored, particularly in shaping the therapeutic trajectory for patients eligible for locoregional interventions like cytoreductive nephrectomy and metastasectomy.

View Article and Find Full Text PDF